188 related articles for article (PubMed ID: 16502486)
1. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
Choi JY; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YK; Kim MS; Kim YA; Song YG; Yong D; Lee K; Kim JM
Yonsei Med J; 2006 Feb; 47(1):63-9. PubMed ID: 16502486
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.
Jellison TK; Mckinnon PS; Rybak MJ
Pharmacotherapy; 2001 Feb; 21(2):142-8. PubMed ID: 11213849
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
5. A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii.
Ackerman BH; Haith LR; Patton ML; Guilday RE; Reigart CL; Stair-Buchmann M
J Burn Care Res; 2013; 34(4):403-12. PubMed ID: 23237825
[TBL] [Abstract][Full Text] [Related]
6. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.
Ozyilkan O; Yalçintaş U; Başkan S
Korean J Intern Med; 1999 Jul; 14(2):15-9. PubMed ID: 10461420
[TBL] [Abstract][Full Text] [Related]
7. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.
Lee NY; Wang CL; Chuang YC; Yu WL; Lee HC; Chang CM; Wang LR; Ko WC
Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460
[TBL] [Abstract][Full Text] [Related]
8. [Cefoperazone-sulbactam plus minocycline in the treatment of extensively drug resistant Acinetobacter infections].
Shi Y; Xu YC; Liu Y; Du W; Rui X; Wang Y
Zhonghua Yi Xue Za Zhi; 2012 Oct; 92(40):2847-50. PubMed ID: 23290215
[TBL] [Abstract][Full Text] [Related]
9. Treatment efficacy of tigecycline in comparison to cefoperazone/ sulbactam alone or in combination therapy for carbapenenm-resistant Acinetobacter baumannii infections.
Li Y; Xie J; Chen L; Meng T; Liu L; Hao R; Dong H; Wang X; Dong Y
Pak J Pharm Sci; 2020 Jan; 33(1):161-168. PubMed ID: 32122844
[TBL] [Abstract][Full Text] [Related]
10. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
Turk Dagi H; Kus H; Arslan U; Tuncer I
Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of efficacies of imipenem, cefoperazone-sulbactam and cefepime in rats with experimental thigh abscess model with multidrug resistant and susceptible Acinetobacter baumannii strains].
Yıldırım MI; Tuğrul HM
Mikrobiyol Bul; 2011 Jul; 45(3):422-9. PubMed ID: 21935775
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections.
Lee YT; Tsao SM; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2013 Sep; 32(9):1211-20. PubMed ID: 23553594
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.
Wood GC; Hanes SD; Croce MA; Fabian TC; Boucher BA
Clin Infect Dis; 2002 Jun; 34(11):1425-30. PubMed ID: 12015687
[TBL] [Abstract][Full Text] [Related]
14. Observation of clinical efficacy of the cefoperazone/sulbactam anti-infective regimen in the treatment of multidrug-resistant Acinetobacter baumannii lung infection.
Wang Q; Huang M; Zhou S
J Clin Pharm Ther; 2022 Jul; 47(7):1020-1027. PubMed ID: 35285526
[TBL] [Abstract][Full Text] [Related]
15. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem.
Levin AS
Clin Microbiol Infect; 2002 Mar; 8(3):144-53. PubMed ID: 12010169
[TBL] [Abstract][Full Text] [Related]
16. [Comparative clinical and epidemiological evaluation of beta-lactam antibiotics in the treatment of intraabdominal infections].
Beketov AS; Sidorenko SV; Pisarev VV; Komarov RM
Antibiot Khimioter; 2003; 48(3):34-41. PubMed ID: 12914120
[TBL] [Abstract][Full Text] [Related]
17. A combination regimen of meropenem, cefoperazone-sulbactam and minocycline for extensive burns with pan-drug resistant Acinetobacter baumannii infection.
Ning F; Shen Y; Chen X; Zhao X; Wang C; Rong Y; Du W; Wen C; Zhang G
Chin Med J (Engl); 2014; 127(6):1177-9. PubMed ID: 24622455
[No Abstract] [Full Text] [Related]
18. Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.
Lai HH; Liou BH; Chang YY; Kuo SC; Lee YT; Chen TL; Fung CP
J Microbiol Immunol Infect; 2016 Jun; 49(3):371-7. PubMed ID: 25081987
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of eravacycline and cefoperazone/ sulbactam against extensively-drug resistant and pan-drug resistant Acinetobacter baumannii isolates from a tertiary hospital in Greece.
Meletis G; Protonotariou E; Gkeka I; Kassomenaki A; Mantzana P; Tychala A; Vlachodimou N; Kourti A; Skoura L
New Microbiol; 2022 Jul; 45(3):210-212. PubMed ID: 35920876
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients.
Winston DJ; Bartoni K; Bruckner DA; Schiller GJ; Territo MC
Clin Infect Dis; 1998 Mar; 26(3):576-83. PubMed ID: 9524826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
